论文部分内容阅读
早在一个多世纪以前,人们就认识到未治疗的原发性甲减患者的垂体窝可以增大。晚近的研究表明,此种增大的垂体腺经甲状腺激素替代治疗后可以缩小。甲减引起高PRL血症的原因不明,有人认为它是由于甲减时的TRH分泌增加所致,即TRH既可增高TSH水平,也可增高PRL水平。但成年甲减病人并不一定都表现有明显的高PRL血症。如将病人与年龄性别相应的对照组比较,其发生率为50％。而用绝对值比较,则其发生率为25％。而且用甲状腺激素替代治疗后,TSH的下降较PRL的下降为快而早。提示两者的机制不尽相同。看来这两种激素的初期升高不象是由TRH分泌引起。本研究旨在进一步揭示这一现象。
More than a century ago, people realized that pituitary fossa of untreated primary hypothyroidism could be enlarged. Recent studies have shown that this increase in the pituitary gland after thyroid hormone replacement therapy can be reduced. Hypothyroidism caused by high PRL hyperlipidemia is unknown, some people think it is due to hypothyroidism TRH secretion increased, that is, TRH can increase TSH levels, but also increase the level of PRL. However, adult hypothyroidism does not necessarily show significant high PRL hyperlipidemia. If the patient and age and sex corresponding control group, the incidence rate of 50%. The absolute value of comparison, then the incidence rate of 25%. And with thyroid hormone replacement therapy, TSH decreased more rapidly than PRL earlier and faster. The mechanisms that suggest both are different. It appears that the initial rise of these two hormones does not seem to be caused by TRH secretion. This study aims to further reveal this phenomenon.